Skip to main content
Clinical Liver Disease logoLink to Clinical Liver Disease
. 2022 Jan 28;19(4):144–147. doi: 10.1002/cld.1171

Telemedicine and Health Disparities

Jennifer C Price 1,, Dinee C Simpson 2
PMCID: PMC9053673  PMID: 35505914

Short abstract

Content available: Author Audio Recording


Abbreviations

HCV

hepatitis C virus

IGI

intervention‐generated inequalities

Listen to an audio presentation of this article.

Telemedicine offers the opportunity to provide clinical services at a distance, thereby bridging geographic and other barriers to medical care. With the need to socially distance during the coronavirus disease 2019 (COVID‐19) pandemic, clinical practices across the United States rapidly transitioned to telemedicine, which quickly became the predominant mode of outpatient care delivery. 1 , 2 While in‐person clinic visits will resume post‐pandemic, telemedicine will remain a major component to health‐care delivery as it fills gaps and satisfies patient needs in ways in‐person clinical visits cannot. 3 Yet, if the technology is not used equitably and uniformly adopted, the move toward telemedicine will exacerbate the deep underlying health‐care disparities exposed by the pandemic. People with limited digital literacy or who lack access to digital devices or reliable broadband Internet, people experiencing homelessness, and people with limited English proficiency have unique challenges accessing telemedicine. 4 It is critical that we identify barriers to telemedicine use and develop solutions to overcome them in order to meet the needs of our patients living with chronic liver disease.

Health Disparities in Liver Disease

A health disparity is defined by Healthy People 2020 as “a particular type of health difference that is closely linked with social, economic, and/or environmental disadvantage”. 5 Health disparities arise from numerous factors including structural racism, systemic inequalities in education, housing, and occupational opportunities and access to other resources. Racial, ethnic, socioeconomic, age, and geographic disparities are well documented across all etiologies of chronic liver disease and have been exacerbated during the COVID‐19 pandemic. 6 , 7

Potential to Generate Inequalities With Telemedicine

On the one hand, telemedicine offers a potential to improve barriers to hepatology care by facilitating access to specialists whom many patients are unable to see in person due to physical distance or other factors. Indeed, telemedicine has been used successfully to manage patients undergoing hepatitis C virus (HCV) treatment, pre‐ and post‐liver transplantation, and other areas of hepatology. 8 Yet telemedicine is susceptible to creating “intervention‐generated inequalities” (IGI), a well‐established public health phenomenon referring to when an intervention designed to improve health increases inequality because it disproportionately benefits more advantaged patients. 9 Indeed, as demonstrated by the conceptual model proposed by Veinot et al, telemedicine poses a particular risk to producing IGIs through pre‐existing disparities in access, as well as inequalities in uptake, adherence, and effectiveness (Fig. 1). Telemedicine relies on digital access, and yet among adults aged 65 or older, only 53% own a smartphone, 59% have broadband access, and 73% use the Internet. 10 , 11 Moreover, racial and ethnic minorities, individuals with lower income, those with lower levels of education, and rural residents are less likely to have home broadband service (Fig. 2). 11 Disparities in access to technology may be compounded by inequitable telemedicine uptake and adherence. For example, online patient portals are often required for telemedicine visits but older adults, racial and ethnic minorities, persons with low health literacy, and individuals with low socioeconomic status are less likely to use these portals. 12 Populations with limited English language proficiency and those with low health literacy may have particular challenges with limited flexibility and poor usability of telemedicine platforms. 13 In addition, privacy concerns are more likely to be expressed by patients with limited health literacy, 14 and distrust in the medical system among Black patients resulting from past and present experiences of racism in health care may adversely impact telemedicine uptake. 15 , 16

FIG 1.

FIG 1

Conceptual model of intervention‐generated inequality. Adapted with permission from Journal of the American Medical Informatics Association. 9

FIG 2.

FIG 2

Percent of US adults who are home broadband users by race/ethnicity (A), income (B), education (C), and community (D). Source: PEW RESEARCH CENTER.

Solutions to Preventing Telemedicine‐Generated Inequalities

Strategies to prevent or mitigate IGIs resulting from telemedicine require solutions at the individual, health systems, and societal level (Table 1). Individual‐level solutions include providing digital skills and telemedicine education/training and resources to inform patients about free or reduced‐cost Internet access. 17 Switching from an opt‐in to universal access patient portal policy can eliminate disparities in portal use by age, race and ethnicity (but not income). 18 Thus, all patients should be offered telemedicine visits and offered more than once. On a health systems level, medical systems must ensure language and interpreter access and user‐centered telemedicine platforms should be designed with reduced structural and technical complexity. 4 , 12 Health systems should utilize a “universal precautions” approach surrounding telemedicine communication. This approach assumes all patients may need health literacy support, and thus provide resources in lay language with visuals and pictographs. 9 We also recommend including social determinants of health in ongoing systems evaluations and reporting of telemedicine usage. Health systems should recruit diverse medical staff and provide clinicians education and training on best practices for conducting telemedicine visits among vulnerable populations. In turn, clinicians need to raise awareness of barriers to telemedicine to health systems leadership when they arise. On a societal level, we should recognize that broadband access is a social determinant of health and expand free or low‐cost access to it. 19 We must invest in device access to facilitate telemedicine visits, technological infrastructure in community‐based settings, and health care navigation services. Finally, we should advocate for greater access to health insurance and payer parity for telemedicine visits. Parity also should be extended between video and audio‐only telemedicine, as eliminating reimbursement for the latter would disproportionately impact certain patient populations.

TABLE 1.

Recommendations to prevent telemedicine‐associated health‐care inequalities at the individual, health systems, and societal levels

Inequality Prevention Level Recommendations
Individual
  • Provide language‐inclusive digital skills and telemedicine education and training

  • Inform patients about free or reduced‐cost Internet access

  • Offer telemedicine visits to all patients and offer more than once

  • Assist patient sign‐up for online portal access

  • Ensure a private space for telemedicine visits without others present

Health Systems
  • Include populations with limited digital and health literacy in platform design

  • Provide language interpreter services

  • Reduce structural and technical complexity of telemedicine platform

  • Recruit diverse medical staff

  • Provide clinician educating and training on telemedicine visits among vulnerable populations

  • Include social determinants of health in evaluation and reporting of telemedicine uptake and outcomes

Societal
  • Expand free or low‐cost home broadband

  • Invest in device access to facilitate telemedicine visits

  • Fund technological infrastructure in community‐based settings and health‐care navigation services

  • Advocate for greater access to health insurance and payer parity for telemedicine visits

Harnessing Telemedicine to Improve Liver Health Disparities

In this review, we have demonstrated ways in which telemedicine can further disadvantage underserved populations with liver disease, and provided some solutions to mitigate this disadvantage. In addition to recognizing the barriers it can generate, however, we must also focus on the opportunities it can create. Telemedicine, when used and distributed equitably and with social determinants in mind, presents an exciting opportunity to increase access to quality care for these groups and thereby improve liver‐related health disparities. For example, minorities are more likely to rely on public transportation and be essential workers, thus limiting their ability and flexibility to travel for specialty care, which is often outside of their immediate geographic area. 6 Telemedicine can make a significant impact upon this disparity in access. Another more specific example includes populations that are significantly less likely to be referred for and receive life‐saving HCV treatment— persons who use drugs and incarcerated individuals. Telemedicine has been successfully used to co‐localize HCV treatment within narcotic treatment programs and within prisons. 20 , 21 Health‐care providers, systems, and law and policy makers must begin to recognize that telemedicine in its current form is not a one‐size‐fits all offering, and must work to address the existing and potential disparities. Continued evaluation and reporting with health equity in mind can help achieve this goal.

Potential conflict of interest: Nothing to report.

References

  • 1. Serper M, Cubell AW, Deleener ME, et al. Telemedicine in Liver Disease and Beyond: Can the COVID‐19 Crisis Lead to Action? Hepatology 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Mehrotra A, Ray K, Brockmeyer DM, Barnett ML, Bender JA. Rapidly converting to “virtual practices”: outpatient care in the Era of COVID‐19. NEJM Catalyst Innovations in Care Delivery 2020. April 1. [Google Scholar]
  • 3. Serper M, Nunes F, Ahmad N, Roberts D, Metz DC, Mehta SJ. Positive early patient and clinician experience with telemedicine in an academic gastroenterology practice during the COVID‐19 pandemic. Gastroenterology 2020;159:1589‐1591.e4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Nouri SN, Khoong EC, Lyles CR, Karliner L. Addressing equity in telemedicine for chronic disease management during the Covid‐19 pandemic. NEJM Catalyst Innovations in Care Delivery 2020. May 4. [Google Scholar]
  • 5. Health People 2020: Disparities . Office of Disease Prevention and Health Promotion. https://wwwhealthypeoplegov/2020/about/foundation‐health‐measures/Disparities. Accessed February 20, 2021.
  • 6. Purnell TS, Simpson DC, Callender CO, Boulware LE. Dismantling structural racism as a root cause of racial disparities in COVID‐19 and transplantation. Am J Transplant 2021;21:2327‐2332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Kardashian A, Wilder J, Terrault NA, Price JC. Addressing social determinants of liver disease during the COVID‐19 pandemic and beyond: a call to action. Hepatology 2021;73:811‐820. [DOI] [PubMed] [Google Scholar]
  • 8. Piao C, Terrault NA, Sarkar S. Telemedicine: an evolving field in hepatology. Hepatol Commun 2019;3:716‐721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Veinot TC, Mitchell H, Ancker JS. Good intentions are not enough: how informatics interventions can worsen inequality. J Am Med Inform Assoc 2018;25:1080‐1088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Pew Research Center . Demographics of Mobile Device Ownership and Adoption in the United States. 2018. Accessed February 20, 2021. http://wwwpewinternetorg/fact‐sheet/mobile/.
  • 11. Pew Research Center . Demographics of Internet and Home Broadband Usage in the United States. 2019. Accessed February 20, 2021. https://wwwpewresearchorg/internet/fact‐sheet/internet‐broadband/.
  • 12. Grossman LV, Masterson Creber RM, Benda NC, Wright D, Vawdrey DK, Ancker JS. Interventions to increase patient portal use in vulnerable populations: a systematic review. J Am Med Inform Assoc 2019;26:855‐870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Sarkar U, Gourley GI, Lyles CR, et al. Usability of Commercially Available Mobile Applications for Diverse Patients. J Gen Intern Med 2016;31(12):1417‐1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Tieu L, Sarkar U, Schillinger D, et al. Barriers and Facilitators to Online Portal Use Among Patients and Caregivers in a Safety Net Health Care System: A Qualitative Study. J Med Internet Res 2015;17:e275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Engaging Patients and Families: How Consumers Value and Use Health IT. National Partnership for Women and Families. 2014. [Google Scholar]
  • 16. Boulware LE, Cooper LA, Ratner LE, LaVeist TA, Powe NR. Race and trust in the health care system. Public Health Rep 2003;118:358‐365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Lyles CR, Sarkar U. Health literacy, vulnerable patients, and health information technology use: where do we go from here? J Gen Intern Med 2015;30:271‐272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Ancker JS, Nosal S, Hauser D, Way C, Calman N. Access policy and the digital divide in patient access to medical records. Health Policy and Technology 2017;6:3‐11. [Google Scholar]
  • 19. Benda NC, Veinot TC, Sieck CJ, Ancker JS. Broadband internet access is a social determinant of health! Am J Public Health 2020;110:1123‐1125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Talal AH, Andrews P, McLeod A, et al. Integrated, co‐located, telemedicine‐based treatment approaches for hepatitis C Virus (HCV) management in opioid use disorder patients on methadone. Clin Infect Dis 2018. [DOI] [PubMed] [Google Scholar]
  • 21. Papaluca T, McDonald L, Craigie A, et al. Outcomes of treatment for hepatitis C in prisoners using a nurse‐led, statewide model of care. J Hepatol 2019;70:839‐846. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Liver Disease are provided here courtesy of American Association for the Study of Liver Diseases

RESOURCES